2025Q4 Bristol-Myers Squibb Company (BMY)

As of mid-February 2026, Bristol-Myers Squibb (BMY) represents one of the most complex investment narratives in the large-cap pharmaceutical sector. The company is currently executing a high-stakes pivot, characterized by a bifurcation of its asset base: a rapidly expanding "Growth Portfolio" that now constitutes nearly 60% of total revenue, battling against the accelerated erosion of a massive "Legacy Portfolio" defined by the loss of exclusivity (LOE) for Revlimid, Pomalyst, and the impending patent cliff for Eliquis.The Fourth Quarter and Full-Year 2025 results, released on February 5, 2026, delivered a critical proof-point in this transition. BMY reported full-year revenues of $48.2 billion, effectively flat year-over-year, which defied bearish consensus expectations of a contraction.1 This stability was achieved through a 17% expansion in the Growth Portfolio, which successfully neutralized a 15% decline in legacy assets. However, the company’s forward guidance for 2026—projecting revenues between $46.0 billion and $47.5 billion—signals that the "trough" of the patent cliff has not yet been fully navigated, with a topline contraction likely before a return to secular growth.3Our analysis suggests that the market is currently pricing BMY as a "value trap," trading at a depressed multiple of ~9.8x 2026 estimated earnings, significantly below the peer group average of 14-16x. This discount reflects deep skepticism regarding the company's ability to replace the revenue vacuum left by Eliquis, which management has guided will suffer a $1.5–$2.0 billion revenue step-down in 2027 due to ex-U.S. generic entry.3However, this bearish view may underappreciate the pipeline optionality, particularly the launch trajectory of Cobenfy (KarXT) in schizophrenia and the label expansion of Breyanzi in oncology. Furthermore, utilizing the Greenwald Franchise Value method, we identify a discrepancy between the market's implied zero-growth valuation and the company's actual capital reinvestment economics, suggesting a fundamental undervaluation of the core franchise.